

**REMARKS**

The Examiner required restriction of one of the following inventions:

- Group I:** including claims 1-16 and 18-27, drawn to a drug that comprises hollow nanoparticles of particle-forming protein, the protein displaying an antibody against a specific cell or tissue and encapsulating a substance to be transferred to the cell for treating a disease; or
- Group II:** including claims 17 and 28, drawn to disease treating methods comprising administering the nanoparticle.

If **Group I** is elected, the Examiner requires the Applicant to elect one of the following embodiments from each of groups (1) (2) and (3):

- (1) one specific antibody (from claim 2), wherein the antibody is:
- (a) a cancer specific antibody, OR
  - (b) an anti-virus protein antibody.
- (2) the elected antibody (1) is displayed on the particle by:
- (c) binding to a ZZ tag fused with the particle-forming protein (Claims 3 and 22); OR
  - (d) binding to streptavidin or its derivative that is ligated to a streptag fused with the particle (Claims 4 and 23).
- (3) one specific modified hepatic B virus surface antigen (HBsAg), wherein:
- (e) the HBsAg lacks some of amino acids in a pre-S

- region (claim 9);
- (f) the HBsAg retains at least N-terminal amino acids 1-20 of the pre-S region (claim 10);
  - (g) the HBsAg retains at least N-terminal amino acids 12-31 of the pre-S region (claim 12);
  - (h) the HBsAg lacks N-terminal amino acids 50-153 of the pre-S region (claim 11); OR
  - (i) the HBsAg lacks N-terminal amino acids 61-164 of the pre-S region (claim 13).

If **Group II** is elected, Applicant is required to elect a disease treating method (4) or (5):

- (4) using the drug of Claim 1; OR
- (5) using the drug of Claim 2.

**Applicant's Election**

Applicants elect the following group, without traverse:

**Group I:** including claims 1-16 and 18-27, drawn to a drug that comprises hollow nanoparticles of particle-forming protein, the protein displaying an antibody against a specific cell or tissue and encapsulating a substance to be transferred to the cell for treating a disease.

In addition, Applicants elect the following species from each of the three embodiments:

- (a) a cancer specific antibody;
- (c) binding to a ZZ tag fused with the particle-forming protein (Claims 3 and 22); AND

- (e) the HBsAg lacks some of amino acids in a pre-S region  
(claim 9);

Applicants reserve the right to file a divisional application for the non-elected claims during the pendency of this application.


**CONCLUSION**


Applicants respectfully request favorable allowance of all the elected claims in the instant application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies to charge payment or credit any overpayment to Deposit Account No. 08-0750 for any additional fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

HARNESS, DICKY & PIERCE, PLC

By  16.57.752

 Donald J. Daley; Reg. No. 34,313  
P.O. Box 8910  
Reston, VA 20195  
(703) 668-8000

DJD/EGH/dmc